Тёмный

Who Has the Upper Hand in Monetizing Gene Therapy for Sickle Cell Disease? CRSP / BLUE ? 

ShareTreck
Подписаться 19 тыс.
Просмотров 530
50% 1

Greetings, fellow investors! Welcome back to ShareTreck. I'm Raj, today I am going to share my thoughts around CRSP and BLUE comparing their progress with Casgevy & Lyfgenia as well as other key parameters.
Well this is my personal opinion, not financial advice.
JOIN THE CHANNEL AS A MEMBER:
Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.
/ @sharetreck
Please subscribe: / @sharetreck
The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
In case of coverage of pharma companies, disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.

Развлечения

Опубликовано:

 

4 авг 2024

Поделиться:

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист
Посмотреть позже
Комментарии    
Далее
How to Make $100 Per Month in Dividends #shorts
0:58
ТЫ С ДРУГОМ В ДЕТСТВЕ😂#shorts
01:00
Protein Bars Are WORSE than Candy Bars!!!
11:31
Просмотров 200 тыс.
ASICS Nimbus 25 After 100 Miles
11:27
Просмотров 165 тыс.
How I Pick My Stocks: Investing For Beginners
13:33
Просмотров 1,2 млн
Самый Невезучий Курьер 😳
0:40
Опасный момент
0:23
Просмотров 2,5 млн